


THE AMENDMENT

In The Claims

1. (Currently Amended) A method for treating ~~cognitive disorders or mnestic disorders~~ which ~~accompany CNS diseases~~ schizophrenia, comprising administering to a patient the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8.
- 2-5. (Cancelled)
6. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically effective dose of the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, or one of its pharmaceutically acceptable salts, in admixture with a pharmaceutically acceptable carrier.
7. (Cancelled)
8. (Currently Amended) A *R*(+)-2-amino-3-hydroxypropanoic acid derivative of formula III, or one of its pharmaceutically acceptable salts;



wherein R is $[[a]]$ hydrogen;

R' is $[[a]]$ hydrogen, or a phenyl(C₂-C₆)alkenyl group, or a gem-diphenyl(C₁-C₆)alkyl group other than benzhydryl, or a gem-diphenyl(C₂-C₆)alkenyl group; or

R and R', together, form a phenyl(C₁-C₆)alkylidene or gem-diphenyl(C₁-C₆)alkylidene group;

R'' is $[[a]]$ hydrogen or a (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl(C₁-C₆)alkyl, phenyl(C₁-C₂)alkyl or phenacetyl group;

the phenyl group or groups being non-substituted or substituted by a halogen atom or by a hydroxy, (C₁-C₃)alkoxy, cyano, nitro or acetyl group;

with the proviso that, when R and R' are both hydrogen, then R" is other than [[a]] hydrogen, (C₁-C₆)alkyl or non-substituted benzyl.

9. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, where R' is a ω -diphenyl(C₂-C₆)alkyl group.
10. (Original) *R*(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.
11. (Original) *R*(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.
12. (Original) *R*(+)-N-[α -phenyl-(2-hydroxy)benzylidene]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.
13. (Previously Presented) The method according to claim 1, wherein said treatment increases glycinergic transmission in said patient.
14. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, wherein R' is a phenyl(C₂-C₆)alkenyl.
15. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is *R*(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid hydrochloride.
16. (Currently Amended) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is methyl *R*(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoate.